T-Cell Receptor

The T-cell receptor (TCR) is a disulfide-linked, membrane-anchored heterodimeric glycoprotein belonging to the immunoglobulin superfamily (IgSF) expressed on the surface of T lymphocytes that recognizes antigenic ligands presented on the surface of target or antigen-presenting cells. In ~95% of human peripheral blood T cells, the antigen-binding clonotypic receptor is an αβ heterodimer (composed of a 40–50 kDa TCRα chain paired with a 40–45 kDa TCRβ chain) that recognizes short peptide fragments (8–11 amino acids on MHC Class I for CD8⁺ cytotoxic T cells, or 13–25 amino acids on MHC Class II for CD4⁺ helper T cells) via MHC restriction, a fundamental principle discovered by Rolf Zinkernagel and Peter Doherty in 1974. The remaining ~1–5% of blood T cells (and a much higher fraction of mucosal intraepithelial lymphocytes) express a γδ TCR heterodimer that recognizes non-peptidic phosphoantigens, lipid antigens on CD1, or stress-induced butyrophilin molecules without classical MHC restriction.

Because the TCRα and TCRβ chains possess minuscule cytoplasmic tails (only 5–12 amino acids long) lacking intrinsic enzymatic activity, surface expression and intracellular signal transduction require non-covalent assembly into an octameric TCR–CD3 holocomplex (TCRαβ · CD3εγ · CD3εδ · CD3ζζ) bearing 10 Immunoreceptor Tyrosine-Based Activation Motifs (ITAMs).

1. Intramembrane Electrostatic Assembly (1:1:1:1 Stoichiometry)

Cryo-electron microscopy structures of the complete human TCRαβ–CD3εγ–CD3εδ–CD3ζζ octamer solved by Dong Chun and colleagues reveal how eight transmembrane α-helices pack into a tight barrel within the lipid bilayer. The transmembrane helix of TCRα contains two conserved positively charged residues (Arg253 and Lys258), and TCRβ contains one conserved Lys288 residue:

• TCRα Lys258 forms an intramembrane electrostatic salt bridge with a pair of negatively charged aspartate/glutamate residues in the transmembrane helices of the CD3εδ heterodimer.
• TCRα Arg253 forms a salt bridge with two aspartate residues in the CD3ζζ homodimer.
• TCRβ Lys288 forms a salt bridge with negatively charged glutamate/aspartate residues in the CD3εγ heterodimer.

2. Diagonal Docking Topology on Peptide–MHC

X-ray crystal structures (first resolved by Don Wiley and Ian Wilson in 1996) show that the TCRαβ variable domains bind across the top of the peptide–MHC (pMHC) groove in a conserved diagonal orientation (typically 30°–70° relative to the long axis of the peptide), placing Vα over the N-terminal half of the peptide and Vβ over the C-terminal half. While antibodies undergo somatic hypermutation to achieve picomolar affinities (K_D ≈ 10⁻⁹–10⁻¹¹ M), TCRs do not undergo somatic hypermutation and bind pMHC with comparatively weak micromolar affinities (K_D ≈ 1–100 μM), yet achieve single-ligand sensitivity through kinetic proofreading, serial triggering, and catch-bond mechanotransduction (where piconewton cytoskeletal pulling forces extend the lifetime of agonist pMHC–TCR bonds).

During T-cell development in the thymus, developing thymocytes rearrange their germline TCR loci using the lymphoid-specific RAG1/RAG2 (Recombination-Activating Gene 1 and 2) endonuclease complex and the non-homologous end joining (NHEJ) machinery (Ku70/Ku80, Artemis, DNA-PKcs, XRCC4, Ligase IV) alongside Terminal Deoxynucleotidyl Transferase (TdT), which adds non-templated N-nucleotides at the coding junctions:

Thymic Positive and Negative Selection

Once a CD4⁺CD8⁺ Double-Positive (DP) thymocyte expresses a complete αβ TCR, it undergoes two stringent quality-control checkpoints in the thymus (~95–98% of thymocytes fail and die):

1. Positive Selection (Thymic Cortex): Cortical thymic epithelial cells (cTECs, expressing the β5t thymoproteasome) test whether the TCR can weakly recognize self-MHC Class I or Class II (low affinity). Thymocytes that fail to bind self-MHC die by neglect; those that bind MHC-I downregulate CD4 to become CD8⁺ single-positive T cells (via Runx3), whereas those that bind MHC-II downregulate CD8 to become CD4⁺ single-positive T cells (via ThPOK).
2. Negative Selection (Thymic Medulla — Central Tolerance): Medullary thymic epithelial cells (mTECs, expressing the transcription factors AIRE and FEZF2 to transcribe thousands of tissue-restricted peripheral antigens such as insulin) and dendritic cells test whether the TCR binds self-peptide–MHC with dangerously high affinity. Self-reactive thymocytes undergo BIM-mediated clonal deletion (apoptosis) or differentiate into Foxp3⁺ regulatory T cells (T_reg).

Coincident nuclear translocation of NFAT, NF-κB, and AP-1 drives transcription of Interleukin-2 (IL2) and the high-affinity IL-2 receptor α-chain (CD25), triggering clonal T-cell expansion (note that Signal 1 from the TCR must be accompanied by Signal 2 costimulation via CD28 binding to CD80/CD86 on the APC; TCR engagement without CD28 costimulation induces T-cell anergy via unaccompanied NFAT-driven E3 ubiquitin ligases such as Cbl-b and GRAIL).

Understanding TCR–CD3 signaling has enabled three transformative classes of clinical cancer immunotherapy:

• Chimeric Antigen Receptor T Cells (CAR-T, e.g., tisagenlecleucel, axicabtagene ciloleucel): Fuse an extracellular antibody single-chain variable fragment (scFv, recognizing native surface antigens like CD19 or BCMA without MHC restriction) to an intracellular CD28 or 4-1BB costimulatory domain and a CD3ζ (3-ITAM) signaling tail.
• Engineered TCR-T Cell Therapy (e.g., afamitresgene autoleucel): Transduces patient T cells with an affinity-enhanced αβ TCR that recognizes intracellular tumor antigens (which account for ~85% of the proteome and are inaccessible to CAR-T scFvs) presented as peptides on specific HLA alleles, such as MAGE-A4 or NY-ESO-1 on HLA-A*02:01.
• ImmTACs and Bispecific T-Cell Engagers (e.g., tebentafusp, blinatumomab): Tebentafusp fuses a picomolar-affinity soluble TCR recognizing a melanocyte gp100 peptide on HLA-A*02:01 to an anti-CD3ε scFv effector arm, recruiting polyclonal patient T cells to lyse metastatic uveal melanoma cells.

• Davis, M. M., & Bjorkman, P. J. (1988). T-cell antigen receptor genes and T-cell recognition. Nature, 334(6181), 395–402. Google Scholar
• Dong, D., Zheng, L., Lin, J., Zhang, B., Zhu, Y., Li, N., ... & Gao, N. (2019). Structural basis of assembly of the human T cell receptor–CD3 complex. Nature, 573(7775), 546–552. Google Scholar
• Rudolph, M. G., Stanfield, R. L., & Wilson, I. A. (2006). How TCRs bind MHCs, peptides, and coreceptors. Annual Review of Immunology, 24, 419–466. Google Scholar
• Courtney, A. H., Lo, W. L., & Weiss, A. (2018). TCR signaling: mechanisms of initiation and propagation. Trends in Biochemical Sciences, 43(2), 108–123. Google Scholar